Healthcare May 27, 2022 11:56 AM (GMT+8) · EqualOcean
Bayer recently announced a new structural adjustment: the establishment of the cancer business unit, the merger of cardiovascular and diabetes, and its name changed to the field of metabolic therapy, effective on June 1, 2022. Bayer will set up a cancer division in China. The newly established cancer department will be led by Han Shuang. She will become a member of the Chinese prescription drug management team, base in Beijing, and report to Zhou Xiaolan, executive vice president and President of Bayer prescription drug division in China. South China, North China and West China will report to Han Shuang from their respective heads of tumor treatment field and the head of tumor marketing department; The current hemophilia treatment team will remain in each branch and report to the director of respiratory treatment in their respective regions. The marketing team will report directly to Hu Ziping, the head of China marketing department. China's CV treatment field team and dia treatment field team will be merged into the cvrm treatment field. The new cvrm team will focus on ensuring the successful listing of kerendia, dorzagliatin and continuous glucose monitoring system (CGM) in China, and actively respond to the upcoming volume procurement of Adalat.

This text is a result of machine translation.